News Column

Study Findings from University Hospital Provide New Insights into Cancer Gene Therapy

June 16, 2014



By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- New research on Biotechnology is the subject of a report. According to news reporting out of Nice, France, by NewsRx editors, research stated, "We characterized, using small RNA sequencing, the miRNA signature at different stages of cSCC development in a mouse model of two-stage chemically induced skin carcinogenesis and we described the tumor-suppressive action of the miR-193b/365a cluster that targets major oncogenic pathways.Incidence of cutaneous squamous cell carcinomas (cSCCs) constantly increases in the Caucasian population. Developing preferentially on precancerous lesions such as actinic keratoses due to chronic sunlight exposure, cSCCs result from the malignant transformation of keratinocytes."

Our news journalists obtained a quote from the research from University Hospital, "Although a resection of the primary tumor is usually curative, a subset of aggressive cSCCs shows a high risk of recurrence and metastases. The characterization of the molecular dysfunctions involved in cSCC development should help to identify new relevant targets against these aggressive cSCCs. In that context, we have used small RNA sequencing to identify 100 microRNAs (miRNAs) whose expression was altered during chemically induced mouse skin tumorigenesis. The decreased expression of the miR-193b/365a cluster during tumor progression suggests a tumor suppressor role. Ectopic expression of these miRNAs in tumor cells indeed inhibited their proliferation, clonogenic potential and migration, which were stimulated in normal keratinocytes when these miRNAs were blocked with antisense oligonucleotides. A combination of in silico predictions and transcriptome analyses identified several target genes of interest. We validated KRAS and MAX as direct targets of miR-193b and miR-365a."

According to the news editors, the research concluded: "Repression of these targets using siRNAs mimicked the effects of miR-193b and miR-365a, suggesting that these genes might mediate, at least in part, the tumor-suppressive action of these miRNAs."

For more information on this research see: miR-193b/365a cluster controls progression of epidermal squamous cell carcinoma. Carcinogenesis, 2014;35(5):1110-1120. Carcinogenesis can be contacted at: Oxford Univ Press, Great Clarendon St, Oxford OX2 6DP, England. (Oxford University Press - www.oup.com/; Carcinogenesis - carcin.oxfordjournals.org)

Our news journalists report that additional information may be obtained by contacting C. Gastaldi, Univ Hosp Nice, Dept. of Pathol, Nice, France. Additional authors for this research include T. Bertero, N. Xu, I. Bourget-Ponzio, K. Lebrigand, S. Fourre, A. Popa, N. Cardot-Leccia, G. Meneguzzi, E. Sonkoly, A. Pivarcsi, B. Mari, P. Barbry, G. Ponzio and R. Rezzonico (see also Biotechnology).

Keywords for this news article include: Nice, Biotechnology, France, Europe, Genetics, Oncology, Cancer Gene Therapy, Squamous Cell Carcinoma

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters